Categories: News

Grey Cloak Tech Completes Successful Pilot Study on its Fuel4Thought™ Migraine Formula with Positive Results

Fuel4Thought™ proprietary Migraine formulation is similar to their recently released Brain Booster, but scientifically designed to try and provide millions of sufferers a natural solution.

LAS VEGAS, Dec. 22, 2020 (GLOBE NEWSWIRE) — Grey Cloak Tech Inc. (OTCQB: GRCK) – (soon to be Healthy Extracts Inc. pending a corporate name change), a company engaged in proprietary development of natural plant-based formulations as well as sales and distribution of cardiovascular and neuro products, is pleased to announce its subsidiary, Ultimate Brain Nutrients™, (UBN) has announced a successful completion of a pilot study for its proprietary Fuel4Thought™ (F4T™) formulation to help with Migraines.

Dr. Gerald Haase, MD. a key consultant to the Medical Advisory Board said, “We were excited to study this unique F4T™ formulation, as previous scientific data had indicated that this combination of natural ingredients could have a positive benefit for Migraines. These initial results were dramatic and the scientific paper has been submitted for publication.”

“Nearly 40 million people suffer from some form of Migraines in just the United States,” stated Duke Pitts, President. “This version of our F4T™ formulation could provide a natural alternative for Migraines and will join our current release of Brain Booster in the middle of 2021. They will be a huge part of attaining our sales goals for the year.”

UBN has two patents issued and three pending on its proprietary formulations. UBN’s products have been 20 years in development with 90 iterations and is supported by 85 clinical studies of its three-main Ingredients. In addition, UBN has filed for an application to the US Food and Drug Administration to make Qualified Health Claims for its migraine formulation.

About Grey Cloak Tech Inc.
Grey Cloak Tech Inc. (OTCQB: GRCK) name change pending to Healthy Extracts Inc.), through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural ingredient cardiovascular and neuro products. For more information, visit the company’s websites:
www.healthyextractsinc.com, www.bergametna.com, www.ubnutrients.com

About Ultimate Brain Nutrients
Grey Cloak’s Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy. UBN’s KETONOMICS® proprietary formulations – targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio. License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms. UBN has five unique formulation patents – two issued and three pending – targeting brain activity, memory, focus, headache and cognitive behavior. Learn more at www.ubnutrients.com.

About BergaMet NA
BergaMet NA, a wholly owned subsidiary of Grey Cloak Technologies (OTCQB: GRCK), is a provider of nutraceutical natural heart health supplements. Based in Nevada, BergaMet researches and develops proprietary, natural, plant-based formulations. BergaMet also provides sales and distribution of natural neuro products that feature superior health technologies based on clinical and doctor supported evidence for maintaining a healthy immune system and improving metabolic syndrome. Learn more at www.bergametna.com.

Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Grey Cloak Tech Inc.:
Info@GreyCloakTech.com 

Corporate Communications:
Grey Cloak Tech Inc.:
www.healthyextractsinc.com 
info@healthyextractsinc.com 

Staff

Recent Posts

Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches

Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…

1 hour ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…

1 hour ago

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…

1 hour ago

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

4 hours ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

4 hours ago